Author Archives: Scalper1

Luxoft Hurt By Deutsche Bank, FX; Stock Plunges But CEO Holds Firm

Already down 28% from Feb. 1 before the open Friday,  Luxoft Holding stock plunged as much as 16% in the stock market today before regaining some of its losses, with shares down 4.5%, near 53, in afternoon trading. Late Thursday, the company delivered Q3 earnings and gave full-year guidance below Wall Street estimates. A tech-outsourcing firm primarily targeting financial services IT and automotive tech markets, Switzerland-based Luxoft said EPS minus items  fell 11% year over year to 72 cents, on revenue that grew 18% to $172 million, for the quarter ended Dec. 31. Analysts polled by Thomson Reuters had expected 80 cents on $175 million. Luxoft stock is now 34% below its all-time high of 80.64 set just Dec. 8. Luxoft went public in June 2013 at 17. In the company’s earnings conference call early Friday, CEO Dmitry Loschin said Luxoft faced tough comps from a year earlier, “material” foreign-exchange headwinds, and offered “discounts to some of our key customers.” He said the discounts were enabled by “our strong performance during the first six months of the year” before uttering Deutsche Bank ( DB ), which he eventually explained. The bad news: Frankfurt-based Deutsche, Luxoft’s No. 1 client, was just coming off another big quarterly loss, prompting layoffs and a five-year restructuring program. The good news: Luxoft just signed a five-year master services agreement with Deutsche, expiring in December 2020, and made it to Deutsche’s shrinking preferred-vendor list. “With that, we believe Deutsche Bank . . . will provide a stable level of revenues for the next 12-14 months for Luxoft, but we are not forecasting significant growth,” Loschin told analysts. Asked by an JPMorgan analyst Alexey Gogolev if Deutsche would require further discounts, Loschin responded: “For sure we don’t expect every quarter to provide discounts to them. Our expectations for the next quarters is to be flat, with some variation up and down. . . . Taking into account the bank’s  position today, there are certain risks. They need to change their IT. This is a good year to make IT changes.” Luxoft said revenue tied to No. 2 client, UBS ( UBS ) rose 36%, and “now comprises 21.5% of our revenues,” said Loschin. “We are very optimistic regarding the upcoming work pipeline. . . . “Further, we have been successfully ramping up other major accounts in this vertical, such as Citigroup ( C ) and Credit Suisse ( CS ). The latter is going through many interesting, for us, transformational initiatives. ” For the first nine months of its fiscal year, financial services outsourcing revenue rose nearly 29% to nearly 69% of Luxoft’s total sales, said Chief Financial Officer Roman Yakushkin. Revenue from automotive and transportation outsourcing — in which car-audio maker Harman International Industries ( HAR ) ranks as its top sector client and No. 3 customer overall — rose 39% to 11.6% of total sales. Technology outsourcing rose 36% to 6.9% of sales. Telecom rose 10.5% to 5.7% of sales. Travel and aviation declined 15% to 4.5% of revenue. And energy increased 5.2% to 2% of sales. UBS analyst Steven Milunovich, in a research note issued Friday, reiterated his buy rating on Luxoft stock, with an 84 price target. “The stock is already down . . . on concerns of exposure to DB, UBS, and Credit Suisse,” he said. “However, the slowdown in constant currency growth, apparently largely due to DB, might cause further weakness. We believe strong performance in other verticals might be sufficient to limit downside, though, and the longer-term outlook remains bright.”  

Baidu Says China Execs Have Offered To Buy Video Wing for $2.8 Bil

China search giant Baidu ( BIDU ) announced Friday that the company has received a non-binding proposal from two Baidu executives to acquire the company’s fast-growing Qiyi video wing for $2.8 billion. Already one of China’s largest online video streaming services, Qiyi is looking to become a bigger force in the country’s video-streaming and moviemaking fields, a nearly $6 billion market that also includes Baidu rivals Alibaba Group ( BABA ), Tencent Holdings ( TCEHY ) and Sohu.com ( SOHU ). Last year, Netflix ( NFLX ) said it wants to begin operating in China, but the streaming media company has expressed uncertainty about its planned move into the country by 2016. Baidu stock jumped on the news and was up 8% in afternoon trading in the stock market today , near 152. But Baidu stock is down 26% this year. The non-binding proposal came from Baidu CEO Robin Yanhong Li and Qiyi CEO Yu Gong, Baidu said. The pair have proposed acquiring all of the outstanding shares of Qiyi owned by Baidu based on an enterprise valuation of U.S. $2.8 billion. Should a special committee formed by Baidu to review the offer approve the deal, Qiyi will remain a strategic partner, although it will be independent. Baidu currently owns 80.5% of Qiyi’s total outstanding shares. The transaction would “significantly help Baidu’s margin improvement,” wrote Summit Research analyst Henry Guo in an industry note Friday. “Currently, Qiyi still operates as a loss-making business due to strong video contents competition among deep-pocket players including Tencent and Alibaba Group. “For the past couple of quarters, the Qiyi business had about 5%-6% of negative operating margin impact to Baidu. According to our estimates, iQiyi, as a stand-alone business, had a negative 40%-50% of operating margin in 2015.” Strong Q3 growth for Baidu’s Qiyi video wing was largely due to the company’s aggressive video content acquisition, said Guo, who added that Qiyi’s “content cost was up 84% year over year in Q3, and we have forecasted it to double year over year in the December quarter.” Last year, Alibaba bought out Youku Toudu, a rival streaming content service provider, for $3.7 billion. Guo added that the “valuation implied in Alibaba’s October 100% acquisition of Youku Tudou hurts Qiyi’s negotiation power as Qiyi looks for extra funding to support its aggressive content strategy.” Baidu is to report Q4 earnings after the close on Feb. 25. Last month, Baidu denied a report that it planned IPOs in China for nine of its subsidiaries, including Qiyi. Image provided by Shutterstock .

Intercept Pharma Spikes On Report That It’s Exploring A Sale

Shares of biotech Intercept Pharmaceuticals ( ICPT ) spiked 30% in early-afternoon trading Friday on a report that the company is exploring a sale. Reuters cited anonymous sources in its report that Intercept has been working with investment bankers this week after it received interest from other companies. Reuters did not name any of the suitors, but Intercept has been a perpetual source of buyout speculation. Gilead Sciences ( GILD ) is a popular choice of buyer due to its overlapping work in liver diseases, and so are big pharmas working in that space such as Bristol-Myers Squibb ( BMY ), Johnson & Johnson ( JNJ ) and Merck ( MRK ). Intercept shares were up about 31% on the stock market today , near 123. An imminent deal would be oddly timed, however, given that Intercept’s lead drug is tied up in a long and uncertain FDA review. Initially the agency set a deadline of Feb. 29 to decide whether to approve Intercept’s obeticholic acid (OCA) for primary biliary cirrhosis (PBC). In December, however, the FDA pushed the deadline out to May 29 to provide time for an advisory committee, or adcom, to review and vote on the application on April 7. The FDA generally calls such committees when it has unresolved issues with the data. Intercept is also studying OCA for the potentially much bigger market in nonalcoholic steatohepatitis (NASH), but safety issues have arisen in its trials. “We doubt that Intercept could or would be acquired before at least an adcom panel to discuss the risk/benefit of the drug for PBC approval, and any indications of interest by an acquirer would be more to just do due diligence and explore scenarios and valuations first,” wrote RBC Capital Markets analyst Michael Yee in a research note. Yee added that an acquirer would likely have to pay up to $5 billion for Intercept but wouldn’t be able to make money off the deal for years since the drug is expected to ramp slowly. This uncertainty over the last few months has helped tamp down Intercept’s stock even more than other biotechs’, as it’s trading at only about a third of its May high of 314.88. Image provided by Shutterstock .